ProKidney CEO Bruce Culleton acquires 500K options

The award's time-based vesting schedule includes three 125,000-share installments through August 15, 2027.

Available on EDGAR 11/03/2026 - 06:52 PM EST Accepted by SEC EDGAR 11/03/2026 - 06:52 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ProKidney Corp. reports that CEO and director Bruce Culleton acquired 500,000 performance-based options under an award originally granted December 3, 2023. On November 2, 2026, the board certified that the performance goal was achieved at 100%. The options cover Class A Common Stock, have a $1.69 exercise price and expire December 3, 2033.

Twenty-five percent vested on November 2, 2026; the remaining 75% vests in three 125,000-share installments on February 15, May 15 and August 15, 2027.

Insider Trade Summary

Grant/Award: 500,000 shares

Grant/Award 1 txn

Insider Culleton Bruce

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee stock option (right to buy) F1	500,000	$0.00	$0.00

Holdings After Transaction: Employee stock option (right to buy) — 500,000 contracts (Direct)

Footnotes (1)

1. F1. This performance-based stock option was granted on December 3, 2023. On November 2, 2026, the Company's board of directors certified achievement of the performance goal at 100%. In addition to the achievement of the performance goal, the options are subject to time vesting requirements under which 25% vested on November 2, 2026 and the remaining 75% vests in equal installments of 125,000 shares on each of February 15, 2027, May 15, 2027 and August 15, 2027.

Key Figures

Options acquired: 500,000 options for Class A Common Stock Exercise price: $1.69 per share Performance goal achieved: 100% +4 more

7 metrics

Options acquired 500,000 options for Class A Common Stock Performance-based award originally granted December 3, 2023

Exercise price $1.69 per share Options for Class A Common Stock

Performance goal achieved 100% Certified by the board on November 2, 2026

Vested portion 25% Vested on November 2, 2026

Remaining time-vesting portion 75% Vests in installments on February 15, May 15 and August 15, 2027

Installment size 125,000 shares Each installment is scheduled for February 15, May 15 and August 15, 2027

Expiration date December 3, 2033 Options for Class A Common Stock

Key Terms

performance-based stock option, performance goal, time vesting requirements

3 terms

performance-based stock option financial

"This performance-based stock option was granted"

performance goal financial

"certified achievement of the performance goal at 100%"

time vesting requirements financial

"subject to time vesting requirements"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did PROK CEO Bruce Culleton acquire?

Bruce Culleton acquired 500,000 performance-based options under an award originally granted December 3, 2023. The board certified on November 2, 2026, that the performance goal was achieved at 100%. The options have a $1.69 exercise price.

When do Bruce Culleton's PROK options vest?

Twenty-five percent vested on November 2, 2026. The remaining 75% vests in equal installments of 125,000 shares on February 15, May 15 and August 15, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Culleton Bruce

(Last) (First) (Middle)

C/O PROKIDNEY CORP

2000 FRONTIS PLAZA BLVD, SUITE 250

(Street)

WINSTON SALEM NORTH CAROLINA 27103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROKIDNEY CORP. [ PROK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$1.69	11/02/2026		A		500,000		(1)	12/03/2033	Class A Common Stock	500,000	$0	500,000	D

Explanation of Responses:

1. This performance-based stock option was granted on December 3, 2023. On November 2, 2026, the Company's board of directors certified achievement of the performance goal at 100%. In addition to the achievement of the performance goal, the options are subject to time vesting requirements under which 25% vested on November 2, 2026 and the remaining 75% vests in equal installments of 125,000 shares on each of February 15, 2027, May 15, 2027 and August 15, 2027.

	/s/ Todd Girolamo, attorney in fact	11/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)